Tumor-associated antigen (patient-derived, mRNA-identified) (TAA (patient-specific, mRNA-based))

Tumor-associated antigens (TAAs) derived from patient-specific tumor-derived mRNA represent a broad and customizable set of protein antigens encoded by genes either overexpressed or mutated uniquely in an individual patient's tumor. They are identified via mRNA sequencing of tumor tissue, enabling personalized immunotherapeutic approaches such as mRNA cancer vaccines. These antigens activate immune responses—predominantly through T cells—against tumor cells and have been leveraged in developing novel cancer immunotherapies, including individualized mRNA vaccines and adoptive cell transfer strategies. While powerful as therapeutic targets, their use presents challenges related to specificity, tumor heterogeneity, and safety, as many TAAs are not exclusive to tumor tissues and may be present at low levels in normal cells, raising concerns for off-target effects and immunogenicity[1][2][3][4][5][6][7].

Other names

Tumor-associated antigens (TAAs)patient-specific tumor antigenspersonalized TAAsmRNA-identified tumor antigenscancer-testis antigensdifferentiation antigensoverexpressed antigens

Presentation of tumor-associated antigens via MHC molecules leads to activation of cytotoxic T lymphocytes, priming the immune system to target and destroy tumor cells expressing these antigens[1][2][3][5].